文献速递细菌感染、耐药与抗菌药物

临床分离鲍曼不动杆菌碳青霉烯类耐药总体状况:系统综述与Meta分析

Overall status of carbapenem resistance among clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该系统综述与Meta分析纳入177项来自不同国家的研究,评估临床分离鲍曼不动杆菌对碳青霉烯类的耐药状况。结果显示对亚胺培南、美罗培南和多利培南的平均耐药率分别为44.7%、59.4%和72.7%,异质性高(I²>50%,P<0.05),未检测到发表偏倚(P>0.05)。作者结论为碳青霉烯类耐药总体较高且全球流行,时间趋势分析显示2000年至2023年耐药率上升。

要点

  • 临床分离鲍曼不动杆菌对亚胺培南、美罗培南和多利培南的平均耐药率分别为44.7%、59.4%和72.7%。
  • 异质性高(I²>50%,P<0.05),Begg与Egger检验未提示发表偏倚(P>0.05)。
  • 时间趋势分析显示2000年至2023年耐药率上升。

核心结论

  • 临床分离鲍曼不动杆菌对碳青霉烯类的总体耐药率相对较高且全球流行。
  • 时间趋势分析显示2000年至2023年耐药率上升。
  • 作者强调在选择治疗方案前进行常规抗菌药物敏感性试验的重要性,以及监测和控制鲍曼不动杆菌耐药模式、寻求新治疗选择以减少耐药株出现和传播并降低治疗失败。

研究设计与样本

  • 系统综述与Meta分析,检索电子数据库,关键词包括Acinetobacter baumannii、resistance、carbapenem、imipenem、meropenem、doripenem等。
  • 经排除后纳入来自不同国家的177项研究。

主要发现

  • 鲍曼不动杆菌对亚胺培南、美罗培南和多利培南的平均耐药率分别为44.7%、59.4%和72.7%。
  • 代表亚胺培南、美罗培南和多利培南耐药的研究中检测到高水平异质性(I²>50%,P<0.05)。
  • Begg与Egger检验未提示发表偏倚(P>0.05)。
  • 时间趋势分析显示2000年至2023年耐药率上升。

关键数值与推荐

  • 鲍曼不动杆菌对亚胺培南的平均耐药率为44.7%。
  • 鲍曼不动杆菌对美罗培南的平均耐药率为59.4%。
  • 鲍曼不动杆菌对多利培南的平均耐药率为72.7%。
  • 异质性I²>50%,P<0.05。
  • 发表偏倚检验P>0.05。

临床怎么用

  • 作者强调在选择治疗方案前进行常规抗菌药物敏感性试验的重要性。
  • 作者强调监测和控制鲍曼不动杆菌耐药模式以及寻求新治疗选择的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to carbapenems, the first-line treatment for infections caused by Acinetobacter baumannii, is increasing throughout the world. The aim of the present study was to determine the global status of resistance to carbapenems in clinical isolates of this pathogen, worldwide. METHODS: Electronic databases were searched using the appropriate keywords, including: 'Acinetobacter' 'baumannii', 'Acinetobacter baumannii' and 'A. baumannii', 'resistance', 'antibiotic resistance', 'antibiotic susceptibility', 'antimicrobial resistance', 'antimicrobial susceptibility', 'carbapenem', 'carbapenems', 'imipenem', 'meropenem' and 'doripenem'. Finally, following some exclusions, 177 studies from various countries were included in this study. The data were then subjected to a meta-analysis. RESULTS: The average resistance rate of A. baumannii to imipenem, meropenem and doripenem was 44.7%, 59.4% and 72.7%, respectively. A high level of heterogeneity (I2 > 50%, P value < 0.05) was detected in the studies representing resistance to imipenem, meropenem and doripenem in A. baumannii isolates. Begg's and Egger's tests did not indicate publication bias (P value > 0.05). CONCLUSIONS: The findings of the current study indicate that the overall resistance to carbapenems in clinical isolates of A. baumannii is relatively high and prevalent throughout the world. Moreover, time trend analysis showed that the resistance has increased from the year 2000 to 2023. This emphasizes the importance of conducting routine antimicrobial susceptibility testing before selecting a course of treatment, as well as monitoring and controlling antibiotic resistance patterns in A. baumannii strains, and seeking novel treatment options to lessen the emergence and spread of resistant strains and to reduce the treatment failure.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ghahramani A, Naghadian Moghaddam MM, Kianparsa J, et al. Overall status of carbapenem resistance among clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. J Antimicrob Chemother. 2024. PMID: 39392464. doi:10.1093/jac/dkae358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。